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e report that the activity of glycogen synthase
kinase-3 (GSK-3) is necessary for the mainte-
nance of the epithelial architecture. Pharma-
cological inhibition of its activity or reducing its expression
using small interfering RNAs in normal breast and skin
epithelial cells results in a reduction of E-cadherin expres-
sion and a more mesenchymal morphology, both of which
are features associated with an epithelial–mesenchymal
W
 
transition (EMT). Importantly, GSK-3 inhibition also stimu-
lates the transcription of Snail, a repressor of E-cadherin
and an inducer of the EMT. We identify NF
 

 
B as a tran-
scription factor inhibited by GSK-3 in epithelial cells that
is relevant for Snail expression. These findings indicate
that epithelial cells must sustain activation of a specific
kinase to impede a mesenchymal transition.
 
Introduction
 
The distinct architecture of epithelia is derived from the inter-
actions of epithelial cells with each other, with the underlying
basement membrane, and, less directly, with mesenchymal
cells in the stroma. Within this complex set of interactions, a
prime determinant of epithelial structure is E-cadherin, a trans-
membrane protein that mediates Ca
 

 
-dependent, homophilic
intercellular adhesion (Thiery, 2002; Nelson and Nusse, 2004).
The central role of E-cadherin in epithelia is evidenced by the
fact that loss of either its expression or function results in the
dissolution of the epithelial architecture and the acquisition of
a mesenchymal phenotype. This process, referred to as the
epithelial–mesenchymal transition (EMT), occurs in the con-
texts of development and tumor progression (Thiery, 2002).
The central importance of E-cadherin for epithelial archi-
tecture leads to the novel hypothesis that epithelial cells may
support signaling pathways that preserve E-cadherin expres-
sion as a means of preventing an EMT. In this connection,
we were intrigued by reports that glycogen synthase kinase-3
(GSK-3), a ubiquitously expressed protein serine kinase, is
active in resting epithelial cells (Papkoff and Aikawa, 1998;
Murray et al., 1999), but that its function in epithelial biology
had not been defined. Our assessment of GSK-3 function in
epithelial cells revealed that its activity is essential for main-
taining epithelial structure because it maintains the expression
of E-cadherin. Inhibition of GSK-3 activity or expression results
in a bona fide EMT. Moreover, we report that one mechanism
by which GSK-3 maintains E-cadherin expression is by inhib-
iting the transcription of Snail, a zinc finger transcriptional
repressor of E-cadherin that is absent in epithelial cells but
expressed in tumors (Batlle et al., 2000; Cano et al., 2000;
Blanco et al., 2002).
 
Results and discussion
 
Initially, we assessed the effects of inhibiting GSK-3 activity in
normal breast epithelial cells (MCF10A) using SB415286, a
highly specific, small molecule inhibitor of GSK-3 (Coghlan et
al., 2000). The ability of SB415286 to inhibit GSK-3 activity
was evidenced by the increased levels of cyclin D1, a protein
subject to GSK-3–dependent proteolysis (Diehl et al., 1998), in
SB415286-treated MCF10A cells, relative to those treated with
DMSO (Fig. 1 A). Inhibiting GSK-3 activity also disrupted the
epithelial morphology of these cells, as evidenced by the loss
of cell–cell contacts (Fig. 1 A).
Loss of E-cadherin and expression of mesenchymal pro-
teins are defining steps in the EMT. Based on our observation
that inhibition of GSK-3 activity reduced cell–cell contacts in
MCF10A epithelial cells, we hypothesized that GSK-3 may be
a regulator of E-cadherin expression and an inhibitor of the
EMT. Supporting these hypotheses, the treatment of MCF10A
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cells with SB415286 reduced the expression of total cellular
E-cadherin protein significantly and induced the expression of
the mesenchymal protein vimentin (Fig. 1 A) without influenc-
ing cell viability (not depicted). Together, these data indicate
that epithelial cells in which GSK-3 activity has been inhibited
manifest changes characteristic of an EMT.
The effects of GSK-3 inhibition can be generalized to
other epithelial cells, as demonstrated by the significantly re-
duced levels of E-cadherin protein in HaCaT skin cells that had
been incubated with the GSK-3 inhibitor (Fig. 1 B). This treat-
ment also increased cyclin D1 expression, indicating the effi-
cacy of SB415286 in HaCaT cells (Fig. 1 B). GSK-3 inhibition
also reduced the levels of E-cadherin mRNA in GSK-3 inhibi-
tor–treated HaCaT and MCF10A cells, relative to controls
(Fig. 1 C). We implemented a small interfering RNA (siRNA)
strategy to reduce expression of both the 
 

 
 and 
 

 
 isoforms of
GSK-3 in MCF10A cells. Cells were transfected with a pool of
eight siRNAs, targeting unique regions of GSK-3
 

 
 and GSK-
3
 

 
 genes, or with a pool of nonspecific sequences (Fig. 1 D,
Scr). Relative to the control pool, the GSK-3
 

 
 and GSK-3
 

 
siRNA pool significantly decreased expression of GSK-3
 

 
 and
GSK-3
 

 
 proteins (Fig. 1 D). Similar to the effect of the GSK-3
inhibitor, GSK-3–specific siRNAs markedly reduced E-cad-
herin mRNA (Fig. 1 D).
We next sought to determine the mechanism by which
GSK-3 regulates E-cadherin expression. Snail, a member of
the zinc finger family of transcriptional repressors, is an estab-
lished suppressor of E-cadherin transcription, and its activity
is an important determinant of the EMT, in the contexts of
both mesoderm development (Carver et al., 2001) and tumor
progression (Batlle et al., 2000; Cano et al., 2000). Snail is ab-
sent in epithelial cells but expressed in tumors, and its expres-
sion has been shown to correlate inversely with tumor grade
(Blanco et al., 2002). We investigated whether GSK-3 regu-
lates E-cadherin expression by repressing Snail expression.
Inhibition of GSK-3 activity in either MCF10A or HaCaT
cells significantly increased Snail mRNA levels (Fig. 2 A).
Snail mRNA levels were also elevated in epithelial cells trans-
fected with GSK-3–specific siRNAs (Fig. 2 A). As evidence
that GSK-3 inhibition alters Snail transcription, we observed
increased activity of a Snail promoter–driven reporter gene in
HaCaT cells treated with SB415286, relative to that measured
in DMSO-treated cells (Fig. 2 B). Increased levels of Snail
protein were also detected in cells treated with the GSK-3 in-
hibitor (Fig. 2 C).
Because of our recent finding that NF
 

 
B drives Snail ex-
pression (Barbera et al., 2004), we explored whether GSK-3 in-
hibits Snail transcription by repressing NF
 

 
B activity. Indeed,
inhibition of GSK-3 activity in HaCaT cells stimulated NF
 

 
B-
dependent reporter gene expression (Fig. 3 A). In addition, we
observed significantly decreased levels of I
 

 
B, an inhibitor of
NF
 

 
B, in SB415286-treated MCF10A cells (Fig. 3 B). Finally,
an NF
 

 
B inhibitor (SN50) suppressed the ability of SB415286
to induce Snail expression (Fig. 3 C). Together, these data indi-
cate that the NF
 

 
B pathway is inhibited by GSK-3 in epithelial
cells, which results in the silencing of Snail expression.
The data presented here indicate that GSK-3, a kinase
that is active in resting epithelial cells (Papkoff and Aikawa,
1998; Murray et al., 1999), is a critical determinant of epithelial
structure and a suppressor of the EMT. This finding implies
that epithelial cells must sustain activation of a specific kinase
to prevent an EMT, a mechanism distinct from that suggested
by previous studies, which have shown that activation of ki-
nases such as Akt (Grille et al., 2003) and ILK (Oloumi et al.,
2004) can promote an EMT. An important implication of our
findings is that endogenous suppressors of GSK-3, such as Wnt
and PI3-kinase, which are frequently activated in carcinoma
cells (Woodgett, 2001), may also inhibit E-cadherin transcrip-
tion and promote an EMT. Our observation that inhibition of
both GSK-3
 

 
 and GSK-3
 

 
 isoforms increased Snail expres-
sion in epithelial cells (Fig. 2 A), whereas inhibition of either
isoform alone had no effect on Snail levels (not depicted), indi-
cates that these isoforms may serve redundant functions in
maintaining epithelial architecture. Thus, we hypothesize that
Figure 1. GSK-3 maintains the epithelial
phenotype. (A) MCF10A cells were incubated
with either DMSO or 25 M SB415286 (Bio-
source International) in 0.5% FBS-containing
medium. Cell morphology was assessed after
72 h by phase contrast microscopy. Expres-
sion of Cyclin D1, Stat-1, E-cadherin, and
vimentin was assessed by immunoblotting.
(B) HaCaT cells were incubated with DMSO
or SB415286, and E-cadherin, Stat-1, and
cyclin D1 expression was assessed as indi-
cated in A. Similar results were obtained in
four independent experiments. (C) E-cadherin
and GAPDH mRNA levels were determined
after 48 h of drug treatment by RT-PCR. (D)
MCF10A cells were cotransfected with GSK-3–
and GSK-3–specific inhibitory RNA pools
( siRNA) or a nonspecific control pool
(Scr). RNA was extracted from these cells 48 h
after transfection, and E-cadherin and GAPDH
mRNA levels were determined by RT-PCR.
GSK-3 and Stat-1 expression was assessed
by immunoblotting.
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GSK-3
 

 
 and GSK-3
 

 
 isoforms serve redundant functions in
epithelial cells, and that mice deficient for both GSK-3
 

 
 and
GSK-3
 

 
 expression will exhibit prominent defects in epithelial
structure and function.
The identification of NF
 

 
B as a novel target of GSK-3
activity that is relevant to the EMT is of considerable interest in
light of a recent report that established NF
 

 
B as a central medi-
ator of the EMT (Huber et al., 2004). However, this study did
not define transcriptional targets of NF
 

 
B that are important
for the EMT. Clearly, Snail is a prime candidate for such an
NF
 

 
B target.
Although we identify NF
 

 
B and Snail as novel targets of
GSK-3 activity that are relevant to the EMT, it is likely that
multiple GSK-3 substrates participate in the regulation of epi-
thelial structure. Upon its phosphorylation by GSK-3, 
 

 
-catenin,
a protein that has been implicated in mesenchymal transitions
(Kim et al., 2002; Liebner et al., 2004), is degraded by the pro-
teosome pathway, resulting in its inability to stimulate TCF/LEF
transcription factors (Beals et al., 1997). TCF/LEF can induce
the expression of genes that influence the EMT, such as vimen-
tin (Gilles et al., 2003), the levels of which are elevated in epi-
thelial cells treated with the GSK-3 inhibitor (Fig. 1 A). Thus,
multiple signaling pathways that control the EMT are likely to
be regulated by GSK-3, substantiating our hypothesis that this
kinase is a central regulator of epithelial structure and function.
It is important to mention that Snail was recently identi-
fied as a direct target of GSK-3 kinase activity (Zhou et al.,
2004), and the two GSK-3 phosphorylation sites identified
were shown to influence Snail protein stability and localization
in tumor cells. In contrast, the present study indicates that, in
epithelial cells, GSK-3 impedes Snail transcription. The data
presented here provide one explanation for why epithelial cells,
which are characterized by high basal GSK-3 activity (Papkoff
and Aikawa, 1998; Murray et al., 1999), express negligible lev-
els of Snail mRNA (Fig. 2; Domínguez et al., 2003; Peinado et
al., 2003). The combined abilities of GSK-3 to block Snail
transcription, promote Snail degradation, and prevent Snail nu-
clear localization indicate that this kinase plays a central role in
regulating Snail expression. Future studies addressing the im-
portance of posttranslational control of Snail by GSK-3 in epi-
thelial cells will be crucial for establishing the relevance of this
mode of regulation for the EMT.
GSK-3 is a central target for the development of therapeu-
tics because it has been implicated in numerous pathologies, in-
cluding diabetes and neurologic disorders (Woodgett, 2001).
Our findings suggest that this kinase is active in epithelial cells
for a very important reason, namely to prevent the acquisition
of a mesenchymal phenotype. Because reduced E-cadherin ex-
pression has been reported to be characteristic of some malig-
nant tumors (Bringuier et al., 1993; Hirohashi, 1998; Kowalski
et al., 2003), our findings indicate that inhibition of GSK-3, an
enzyme that maintains E-cadherin expression, will not prove to
be a reasonable therapeutic strategy because it has the potential
to alter epithelial function significantly.
Figure 2. GSK-3 inhibits Snail transcription in epithelial
cells. (A) MCF10A and HaCaT cells were either incu-
bated with 25 M of the GSK-3 inhibitor SB415286 or
with DMSO in 0.5% FBS-containing medium. Alternatively,
these cells were transfected with GSK-3– and GSK-3–
specific inhibitory RNA pools ( siRNA) or a nonspe-
cific control pool (Scr). Snail and GAPDH mRNA levels were
assessed by reverse transcription, followed by PCR. GSK-3
and Stat-1 expression was assessed by immunoblotting.
(B) HaCaT cells were cotransfected with a Snail promoter–
driven and a control -galactosidase reporter construct.
These transfectants were then incubated with DMSO or
SB415286, as described in A, for 24 h. Data are reported
as relative luciferase activity (normalized to -galactosidase
activity),  SD, and are representative of three independent
experiments. (C) MCF10A and HeLa cells were treated
with SB415286 as described in A, and Snail expression
was assessed by immunofluorescence.
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Materials and methods
 
Cells
 
HaCat and HeLa cells were provided by A. Toker (Beth Israel Deaconess
Medical Center, Boston, MA). MCF10A cells were provided by J. Brugge
(Harvard Medical School, Boston, MA).
 
Analysis of protein expression
 
Cells were extracted in RIPA buffer. Equivalent amounts of total cellular
protein extracted from these cells were subjected to SDS-PAGE and trans-
ferred to nitrocellulose. The antibodies used for immunoblotting were as
follows: GSK-3 monoclonal antibody (Upstate Biotechnology), rabbit anti–
cyclin D1 (Santa Cruz Biotechnology, Inc.), rabbit anti–Stat-1 (Santa Cruz
Biotechnology, Inc.), mouse anti–E-cadherin (Santa Cruz Biotechnology,
Inc.), rabbit antivimentin (Santa Cruz Biotechnology, Inc.), mouse anti-–
I
 

 
B 
 

 
 (Cell Signaling), and HRP-conjugated secondary antibodies (Pierce
Chemical Co.).
 
Luciferase assays
 
HaCaT cells were cotransfected transiently using Lipofectin (Life Technolo-
gies) with a Snail promoter luciferase reporter construct (composed of hu-
man snail promoter sequences 
 

 
869 to 59) and a control 
 

 
-galactosidase
reporter construct (pCS2-(n)-
 

 
gal; Promega). For NF
 

 
B studies, HaCaT
cells were transfected with a luciferase construct controlled by sequential
NF
 

 
B binding sites (pNF-
 

 
B-Luc; CLONTECH Laboratories, Inc.) and a
control renilla luciferase construct (pRL-TK renilla luciferase; Promega). Af-
ter incubation for 12 h, cells were treated with the indicated drugs (Fig. 3
A) for an additional 15 h. Luciferase and 
 

 
-galactosidase activities were
measured according to the manufacturer’s instructions (Promega) using a
luminometer and a UV/Vis spectrophotometer, respectively. Data are re-
ported (Fig. 3 A) as the mean (
 
 
 
SD) relative promoter activity obtained
from triplicate wells.
 
Analysis of mRNA expression
 
mRNA was purified from the indicated cell lines using the RNEasy kit
(QIAGEN) according to the manufacturer’s recommended protocol. 2 
 

 
g
RNA was added to RT-PCR reactions containing the indicated primers at a
concentration of 0.6 
 

 
M. After a 55
 

 
C/30-min reverse transcription step,
Snail mRNA was PCR amplified in 32 cycles for 1 min at each of the fol-
lowing temperatures: 94
 

 
, 62
 

 
, and 72
 

 
C. Likewise, E-cadherin mRNA
was PCR amplified in 25 cycles for 1 min at each of the following temper-
atures: 94
 

 
, 55
 

 
, and 72
 

 
C. PCR products were analyzed on 1% aga-
rose gels. The sequences of amplification primers were as follows: Snail
forward, GGGCAGGTATGGAGAGGAAGA; Snail reverse, TTCTTCTG-
CGCTACTGCTGCG; E-cadherin forward, CAGCACGTACACAGCCC-
TAA; E-cadherin reverse, GCTGGCTCAAGTCAAAGTCC; GAPDH
forward, CCTGGCCAAGGTCATCCATGAC; and GAPDH reverse, CAT-
GTAGGCCATGAGGTCCACCAC.
 
siRNA experiments
 
GSK-3
 

 
, GSK-3
 

 
, and control siRNA pools were designed and synthe-
sized by Upstate Biotechnology. Cells at 60% confluence were transfected
in penicillin/streptomycin-free medium with 20 
 

 
M of the indicated siRNA
using TKO lipid (Mirus) according to the manufacturer’s recommended
protocol. Cells were harvested 48 h after transfection.
 
Immunofluorescence
 
Cells were fixed in 2% PFA, permeabilized in 0.2% Triton X-100 and 1
mM EGTA, blocked for 30 min in 1% albumin/5% donkey serum, and in-
cubated overnight at 4
 

 
C with a Snail-specific (Domínguez et al., 2003)
or control rabbit serum in blocking buffer (at a 1:20 dilution). The cells
were then incubated with a fluorescein-conjugated donkey anti–rabbit IgG
(Jackson ImmunoResearch Laboratories) in blocking buffer (at a 1:150
dilution) for 30 min. Snail expression was analyzed using an inverted
fluorescent microscope (Diaphot 300; Nikon).
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